Treatment of heart failure with reduced ejection fraction (HFrEF) is well-established with a wealth of evidence from clinical trials that support the use of all standard-of-care therapies for CHF. ACE inhibitors or AIIRAs, beta blockers, and loop diuretics are used for the first-line treatment of HFrEF patients. Branded agents—Novartis’s Entresto and Amgen’s Corlanor—are also approved for use in this CHF subpopulation. However, calcium-channel blockers are contraindicated in this population. The HFrEF Treatment Algorithm offers insight into prescribing patterns in CHF subpopulation with relatively established treatment guidelines.
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed HF patients with reduced ejection fraction? What are the quarterly trends in prescribing among recently treated and newly diagnosed HFrEF patients?
- How have Amgen’s Corlanor and Novartis’ Entresto been integrated into the treatment algorithm for HFrEF?
- What proportion of HFrEF patients receive drug therapy within one year of diagnosis, and how quickly?
- What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of HFrEF patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated HFrEF patients?